uniQure N.V. (QURE) Logo
uniQure N.V. (QURE) symbol, logo with name and high resolution download options.
About uniQure N.V. (QURE)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntingtonâs disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Get uniQure N.V. (QURE) Logo via API
Integrate this logo into your application with a single API call
Why Use Our Stock Logo API?
Fast Delivery
<100ms response time via global CDN
Enterprise-Ready
99.99% uptime SLA with GDPR compliance
Multiple Formats
SVG, PNG, WebP - scalable to any size
400k+ Logos
Stocks, ETFs, Crypto, Banks, and more
Where to Use Stock Logos
Trading Platforms
Real-time stock displays with instant logo loading
Portfolio Apps
Visualize holdings with recognizable brand logos
Financial Dashboards
Enhance market data with company branding
News & Research
Illustrate articles with accurate company logos
Frequently Asked Questions
Need Stock Logos for Your Application?
Access 380,000+ company logos via our simple REST API. Perfect for trading platforms, portfolio apps, and financial dashboards.